Anuh Pharma Ltd
Anuh Pharma Q3 FY23 earnings call: Revenue & Margins
Q3 FY23 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q3 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Operating Revenue for the 3 months ended 31/12/2022: Rs. EBITDA for Q3 FY23: Rs.
From Anuh Pharma Ltd's Q3 FY23 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Operating Revenue for the 3 months ended 31/12/2022: Rs. 138.73 Cr, up 21% QoQ (from Rs. 115.07 Cr in the previous quarter).
- Operating Revenue for the 9 months ended 31/12/2022: Rs. 370.18 Cr, up 3% YoY (from Rs. 357.68 Cr for same period last year).
- Total revenue for 9M FY23: Rs. 375.25 Cr vs Rs. 361.84 Cr in 9M FY22 (3% growth).
- Export sales in 9M FY23: USD 2.65 Million vs USD 1.67 Million in 9M FY22, indicating strong export growth.
- Future outlook expects revenue growth from new product launches (Vildagaliptin, Sulfadimethoxine, Citicoline sodium) and regulatory filings (CEP for Azithromycin, Gliclazide, Sulfadoxine; WHO prequalification for Isoniazid).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation does not explicitly mention specific capex amounts or new plant/project financials.
- A dedicated 10,000 sq. ft. in-house R&D facility is operational with 16 scientists for new product/process development and manufacturing improvements.
- The company aims to launch new products developed by R&D in the next 3 months: Vildagliptin, Sulfadimethoxine, and Citicoline sodium.
- They expect CEP (Certificate of Pharmaceutical Product) for Azithromycin, Gliclazide, and Sulfadoxine within the year; WHO prequalification for Isoniazid is also expected.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…
Frequently Asked Questions
What were Anuh Pharma Ltd Q3 FY23 results?
Operating Revenue for the 3 months ended 31/12/2022: Rs. EBITDA for Q3 FY23: Rs.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
The presentation does not explicitly mention specific capex amounts or new plant/project financials. - A dedicated 10,000 sq.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.